Abstract：Objective To investigate the changes and significance of peripheral blood T lymphocyte subsets in the course of Clostridium difficile infection.Methods A total of 31 patients with Clostridium difficile infection admitted to The First Affiliated Hospital of Gannan Medical College from January 2018 to February 2020 were selected as the observation group,and 32 normal physical examination subjects during the same period were selected as the control group.The levels of peripheral blood T lymphocyte subsets were compared between the two groups,and the levels of peripheral blood T lymphocyte subsets of patients with different severity of Clostridium difficile infection were compared.Results The levels of CD3+,CD4+and CD8+in the observation group were lower than those in the control group,the differences were statistically significant (P＜0.05).The levels of CD3+,CD4+and CD8+in patients with mild to moderate infections and patients with severe infections were lower than those in the control group,the differences were statistically significant (P＜0.05).There was no statistical difference in CD3+in peripheral blood between mild and moderate infection and severe infection (P＞0.05).The levels of CD4+and CD8+cells in severely infected patients were lower than those in mild-moderate infected patients,and the differences were statistically significant (P＜0.05).Conclusion Cellular immunosuppression was observed in patients infected with Clostridium difficile,the levels of CD4+ and CD8+cells in patients with different degrees of infection showed a gradually decreasing trend,and the decrease was most significant in severely infected patients.The detection of T lymphocyte subsets is helpful for clinical immunotherapy and prognostic evaluation
Ostroumov D，Fekete-Drimusz N，Saborowski M，et al.CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J].Cell Mol Life Sci，2018，75（4）：689-713.
[7]
Yang Y，Qin Z，Du D，et al.Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer[J].Cardio Intervent Radiol，2019，42（1）：48-59.
[8]
Dial S，Delaney JA，Barkun AN，et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease[J].JAMA，2005，294（23）：2989-2995.
[9]
陈冬梅，陈求刚，陈菊香.艰难梭菌性肠炎21例[J].广东医学，2000，21（6）：519.
[10]
Lo Vecchio A，Zacur GM.Clostridium difficile infection：an update on epidemiology，risk factors，and therapeutic options[J].Curr Opin Gastroenterol，2012，28（1）：1-9.
[11]
Zilberberg MD，Reske K，Olsen M，et al.Risk factors for recurrent Clostridium difficile infection（CDI）hospitalization among hospitalized patients with an initial CDI episode：a retrospective cohort study[J].BMC Infect Dis，2014，14（1）：1-8.
[12]
Rineh A，Kelso MJ，Vatan sever F，et al.Clostridium difficile infection：Molecular pathogenesis and novel therapeutics[J].Expert Rev Anti Infect Ther，2014，12（1）：131-150.
[13]
Bobo LD，El Feghaly RE，Chen YS，et al.MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation[J].Infect Immu，2013，81（3）：713-722.
[14]
Zhu Z，Schnell L，Müller B，et al.The antibiotic bacitracin protects human intestinal epithelial cells and stem cellderived intestinal organoids from Clostridium difficile toxin TcdB[J].Stem Cells Int，2019，11（6）：1-8.
[15]
Madan R，Petri WA Jr.Immun e responses to Clostridium difficile infection[J].Trends Mol Med，2012，18（11）：658-666.
Shah PJ，Vakil N，Kabakov A.Role of intravenous immune globulin in streptococcal toxic shock syndrome and Clostridium difficile infection[J].Am J Health Syst Pharm，2015，72（12）：1013-1019.
[19]
Rees WD，Steiner TS.Adaptive immune response to Clostridium difficile infection：A perspective for prevention and therapy[J].Eur J Immunol，2018，48（3）：398-406.
京公网安备 11010502046607号